Asia-Pacific CAR T-Cell Therapy Market Crosses $1.7Bn : Ken Research Tracks Gene Editing as the Core Growth Driver
Asia-Pacific CAR T-Cell Therapy Market Hits $1.7Bn in 2024: Ken Research Finds Gene Editing Surge | Ken Research Executive Summary The Asia-Pacific CAR T-Cell Therapy Market, valued at USD 1.7 billion in 2024 , is on a transformative growth trajectory projected to reach USD 8.0 billion by 2030 , expanding at approximately 27% CAGR . Ken Research analysis confirms this explosive acceleration is driven by rapid gene-editing advancements, mounting hematologic cancer burden exceeding 1 million new cases globally in 2024 , and unprecedented government investment in precision oncology across China, Japan, South Korea, India, and Australia. Japan trials have recorded remission rates of 80% in blood cancer patients, establishing APAC as a benchmark for cell therapy efficacy. (Source: Ken Research proprietary five-year historical dataset and forward-looking forecast model; full report available at kenresearch.com .) Key Takeaways Market valued at USD 1.7 billion in 2024 , proje...